All sponsors

Eikon Therapeutics $EIKN

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS6
PHASE 3 / 2-32
RECRUITING5
READOUTS ≤12 MONTHS2
Open Eikon Therapeutics on the live radar map → 📅 $EIKN readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
EIK1001
NCT06246110
P2Active, not recruitingNSCLC702026-12
IMP1734
NCT06253130
P1/2RecruitingAdvanced Solid Tumor1562027-06-01 (+16 mo)
EIK1004-001
NCT06907043
P1/2RecruitingAdvanced Solid Tumors1302028-12 (+24 mo)
EIK1005
NCT07262619
P1/2RecruitingAdvanced Solid Tumors; MSI-H or dMMR Advanced Solid Tumors1602029-03
EIK1001
NCT06697301
P2/3RecruitingAdvanced Melanoma7402035-12
TeLuRide-008
NCT07365319
P2/3RecruitingNon Small Cell Lung Cancer (Squamous or Non Squamous); Stage 4 NSCLC7502035-12-31